{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Senan S"],"pubmed_abstract":["Background
The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.Materials and methods
Patients with unresectable, stage III NSCLC and no disease progression after ≥2 cycles of platinum-based, concurrent CRT were randomized 2 : 1 to receive durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months) or placebo, 1-42 days after"],"journal":["ESMO open"],"pagination":["100410"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9058904"],"repository":["biostudies-literature"],"pubmed_title":["Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial."],"pmcid":["PMC9058904"],"pubmed_authors":["Hui R","Paz-Ares L","Dennis PA","Senan S","Wu YL","Antonia SJ","Vicente D","Mann H","Ozguroglu M","Villegas A","Faivre-Finn C","Daniel D","Murakami S"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.","description":"Background
The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.Materials and methods
Patients with unresectable, stage III NSCLC and no disease progression after ≥2 cycles of platinum-based, concurrent CRT were randomized 2 : 1 to receive durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months) or placebo, 1-42 days after","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-31T01:07:06.559Z","creation":"2025-04-04T11:32:16.109Z"},"accession":"S-EPMC9058904","cross_references":{"pubmed":["35247871"],"doi":["10.1016/j.esmoop.2022.100410"]}}